Skip to main content
Premium Trial:

Request an Annual Quote

Bioneer Gets CE Mark for HBV Assay

NEW YORK — Bioneer said on Tuesday that it has received CE-IVD marking for its AccuPower hepatitis B virus quantitative PCR kit.

In late 2018, the South Korean company received CE-IVD marking for its AccurPower RT-PCR-based HIV-1 quantitative analysis kit, and about a year later, its AccuPower RT-PCR kit for hepatitis C was CE marked. All three kits run on the company's CE-marked ExiStation system. 

"With the certification of [our] HBV quantitative analysis kit, we have completed marking of all three major items of molecular diagnostics," Bioneer said in a statement. "Based on this, we will increase our participation in national bidding and accelerate expansion of distributors in overseas countries," such as those in Europe, Southeast Asia, and Africa, the firm added.

Bioneer noted that HIV, HBV, and HCV testing represents about two thirds of the world's $9.9 billion molecular diagnostics market.

Bioneer also recently submitted a Wuhan coronavirus diagnostic test kit for emergency use assessment and listing to the Korea Centers for Disease Control and Prevention.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.